ERBB2 and breast carcinoma: In the past two decades, treatment advances and the rise of monoclonal antibodies have improved survival outcomes for HER2-positive advanced breast cancer patients, and targeted therapies are approved for multiple lines in the treatment pathway for HER2-positive mBC [6].